CORT Q2 2025 Earnings — Corcept Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena

CORTCorcept Therapeutics Incorporated

$4B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$194M+18.7% YoY

Gross Profit

$191M98.2% margin

Operating Income

$27M13.7% margin

Net Income

$35M18.1% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

+23.7%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$44M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$802M

Total Liabilities

$166M

Stockholders' Equity

$636M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$194M	$164M	+18.7%
Gross Profit	$191M	$161M	+18.4%
Operating Income	$27M	$36M	-25.1%
Net Income	$35M	$35M	-1.0%